by Peter Sullivan · January 13, 2019
Sen. Cory Booker (D-N.J.) is trying to overcome doubts that he is too close to the pharmaceutical industry ahead of an expected presidential campaign.
The progressive criticism of Booker reached a crescendo in early 2017 when he voted against a budget amendment calling for importing drugs from abroad.
The line of attack played into broader fears from progressives that Booker is not tough enough on corporations in general, including Wall Street.
“Cory Booker And A Bunch Of Democrats Prove Trump Right On Big Pharma,” read a headline in HuffPost.
Booker argued at the time that he supports importing drugs but that the measure lacked standards to ensure the drugs being brought into the country are safe.
But on Thursday, Booker attempted to show he is tough on drug companies, appearing alongside socialist Sen. Bernie Sanders (I-Vt.), a potential presidential rival, at a press conference on lowering drug prices.
Booker spoke out in strong terms against drug companies and the “outrageous and unjustifiably high cost of prescription drugs.”
Some progressives say appearing with Sanders and signing onto drug pricing bills with him was a good step, but they still have doubts about Booker.
“It is meaningful that he recognized the error of his ways and has come in support of some important reforms of the pharmaceutical industry,” said Neil Sroka, communications director for the progressive group Democracy for America.
“But there’s overriding concern about Cory Booker’s willingness to confront corporate power in all of its forms,” Sroka added, referencing his positions on Wall Street and education in addition to drugs.
Running in a race against progressive standard-bearers like Sanders and Sen. Elizabeth Warren (D-Mass.) could put a spotlight on perceptions Booker does not sufficiently stand up to corporations.
The sweeping legislation Booker supported on Thursday, though, is fiercely opposed by the pharmaceutical industry.
The bills would allow Medicare to negotiate drug prices, allow importation of drugs from Canada, and strip monopolies from drug companies if their prices are above those in other wealthy countries.
Peter Maybarduk, a drug pricing expert at the progressive group Public Citizen, declined to comment on Booker’s history on drug pricing issues, but noted that on Thursday “he has signed onto a very serious piece of legislation that the pharmaceutical lobby will do everything it can to beat.”
Booker defended himself on Thursday when asked about the 2017 vote, saying “it was a late-night messaging amendment” and that he quickly went to work in the following days to draft a revised importation bill that did have enough safety standards.
“I’ve always supported imports, and we have a piece of legislation right now that will ensure safety, will drive down costs to taxpayers and will give people access to prescription drugs,” Booker said.
He then referenced another progressive priority he has signed on to: “This should be an issue of American right to quality health care, it’s why I support Medicare for All.”
New Jersey is home to the headquarters of a slew of pharmaceutical companies, and lawmakers traditionally champion their home-state industries.
“Like every senator or representative, he’s pitching for the home team and the home team in New Jersey is pharma,” said Ross Baker, a political science professor at Rutgers University.
Booker has also sought to tamp down questions about his fundraising from pharmaceutical companies.
Booker raised more money from the pharmaceutical industry in 2014 than any other senator, according to the Center for Responsive Politics.
In 2017, Booker announced he was putting a “pause” on taking contributions from drug companies “because it arouses so much criticism.”
Last year, he stopped taking money from all corporate PACs.
“We need to get our politics away from money, that’s why we need to end Citizens United,” Booker said Thursday. “And the pharmaceutical industry is a great example.”
“We have an industry right now that has been able to stop the government from negotiating fairer prices, from using our market leverage to negotiate fairer prices,” Booker said. “That’s outrageous. And so to what Sen. Sanders has said and some of my congressional colleagues have said: Enough is enough.”
The Hill · by Peter Sullivan · January 13, 2019